Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET Â | Source: Scancell Holdings Plc SCOPE trial…
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tbingen
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting…